Author

A. C. M. Boon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Research Focus:drug response / drug discovery· 4 Organism:mouse· 3 Assay:proteomics· 3 Research Focus:benchmarking· 2 Organism:human· 2 Organism:rat· 2

Frequent Co-Authors

J. B. Case· 4 shared M. S. Diamond· 4 shared T. L. Bricker· 4 shared T. L. Darling· 4 shared H. H. Harastani· 3 shared A. L. Bailey· 2 shared P.-Y. Shi· 2 shared R. E. Chen· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

J. B. Case

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

bioRxiv · Nov 22, 2023 · PreprintImmunology

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters

B. Ying, T. L. Darling, P. Desai, C.-Y. Liang, I. P. Dmitriev, N. Soudani, T. L. Bricker, E. A. Kashentseva, H. H. Harastani, A. G. Schmidt, D. T. Curiel, A. C. M. Boon, M. S. Diamond

This paper shows a bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 in mice and hamsters through mucosal immunity, despite poor serum neutralizing antibody responses.

bioRxiv · May 4, 2023 · PreprintMicrobiology

Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters

J. B. Case, S. M. Scheaffer, T. L. Darling, T. L. Bricker, L. J. Adams, H. H. Harastani, R. Trende, S. Sanapala, D. H. Fremont, A. C. M. Boon, M. S. Diamond

This paper evaluates the pathogenicity of SARS-CoV-2 BQ.1.1 and BA.5.5 variants in multiple rodent models, finding increased virulence in transgenic mice but not in conventional mice or hamsters.

bioRxiv · Apr 28, 2023 · PreprintMicrobiology

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

A. J. Schmitz, J. S. Turner, Z. Liu, I. D. Aziati, R. E. Chen, A. Joshi, T. L. Bricker, T. L. Darling, D. C. Adelsberg, W. B. Al Soussi, J. B. Case, T. Lei, M. Thapa, F. Amanat, J. A. O'Halloran, , A. H. Ellebedy

A vaccine-induced human monoclonal antibody neutralizes SARS-CoV-2 and variants, reducing lung inflammation and viral load in hamsters.

bioRxiv · Mar 24, 2021Immunology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection

E. S. Winkler, P. Gilchuk, J. Yu, A. L. Bailey, R. E. Chen, S. J. Zost, H. Jang, Y. Huang, J. D. Allen, J. B. Case, R. E. Sutton, R. H. Carnahan, T. L. Darling, A. C. M. Boon, M. Mack, , M. Diamond

This study shows that neutralizing antibodies against SARS-CoV-2 need intact Fc functions and monocytes for optimal therapeutic protection in animal models.

bioRxiv · Dec 28, 2020Immunology

JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis

J. Son, S. Huang, Q. Zeng, T. L. Bricker, J. B. Case, J. Zhou, R. Zang, Z. Liu, X. Chang, H. H. Harastani, L. Chen, M. F. Gomez Castro, Y. Zhao, H. P. Kohio, G. Hou, , S. Ding

The paper identifies JIB-04 as a broad-spectrum antiviral that inhibits SARS-CoV-2 replication and coronavirus pathogenesis in vitro and in vivo.

bioRxiv · Sep 24, 2020Microbiology